Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Vanda Pharmaceuticals Inc.

VNDA Nasdaq Pharmaceutical Preparations Financials FY2016–FY2025

Last close · Oct 23, 2026

$4.01

1.0%
Compare
Revenue Total sales reported in the income statement.
$216M
8.7% vs prior year
Operating margin Operating income as a share of revenue.
−70.0%
49.5 pts
Net income Profit after all expenses, interest and tax.
−$220M
Free cash flow Cash from operations minus capital spending.
−$110M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap Last close times the latest diluted share count, so it is approximate.
$242M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
—
On −$4.64 EPS (TTM)

What Vanda Pharmaceuticals Inc. does

No business description yet.

Legal name
Vanda Pharmaceuticals Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K · Feb 12, 2026
Accession · CIK
0001628280-26-007460
0001347178

Revenue and margins

Vanda Pharmaceuticals Inc. had $216M of revenue in fiscal 2025, up 8.7% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was −$110M in fiscal 2025, −51.1% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Vanda Pharmaceuticals Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 1.3%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Vanda Pharmaceuticals Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $433M$135M$136M$102M$84.9M
Current ratio 6.4x5.7x4.9x4.4x2.4x
Quick ratio 6.4x5.7x4.9x4.4x2.4x
Total assets $594M$634M$648M$656M$489M
Total liabilities $88.9M$107M$104M$118M$162M
Shareholders' equity $505M$527M$545M$539M$327M
Net debt (− = net cash) —————

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive ✕ ✕ ✓ ✓ ✓ ✓ ✓ ✓ ✕ ✕
Cash from operations is positive ✕ ✕ ✓ ✓ ✓ ✓ ✓ ✓ ✕ ✕
Return on assets rose — ✓ ✓ ✓ ✕ ✓ ✕ ✕ ✕ ✕
Cash from operations exceeds net income ✓ ✓ ✓ ✕ ✓ ✓ ✓ ✓ ✓ ✓
Debt fell relative to assets — — — — — — — — — —
Current ratio rose — ✕ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕
Share count didn't rise — ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕
Gross margin rose — — — — — — — — — —
Revenue rose relative to assets — ✓ ✕ ✕ ✕ ✕ ✕ ✕ ✓ ✓
F-score — / 33 / 75 / 74 / 74 / 75 / 73 / 73 / 72 / 72 / 7
Accruals ratio −4.7%−6.5%−1.8%17.1%−5.6%−5.5%−4.2%−1.6%−0.5%−19.4%
Altman Z'' −0.35−1.257.108.759.2910.008.858.096.910.13

10 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $146M $165M $193M $227M $248M $269M $254M $193M $199M $216M
Research and development $29.2M $38.5M $43.6M $48.6M $55.6M $75.4M $85.8M $76.8M $74.4M $109M
Operating income −$18.6M −$16.9M $21.7M $22.8M $27.2M $42.2M $6.3M −$14.0M −$40.7M −$151M
Pretax income −$17.9M −$15.4M $25.3M $29.0M $31.7M $42.4M $11.3M $6.3M −$22.9M −$139M
Income tax $0.1M $0.1M $0.1M −$86.5M $8.3M $9.2M $5.0M $3.8M −$4.0M $81.8M
Net income −$18.0M −$15.6M $25.2M $116M $23.3M $33.2M $6.3M $2.5M −$18.9M −$220M
Diluted EPS −$0.41 −$0.35 $0.48 $2.11 $0.42 $0.58 $0.11 $0.04 −$0.33 −$3.74
Diluted shares 0.04B 0.04B 0.05B 0.05B 0.06B 0.06B 0.06B 0.06B 0.06B 0.06B
Cash flow
Cash from operations −$8.1M −$2.0M $30.0M $45.9M $51.8M $64.2M $32.0M $12.8M −$15.8M −$109M
Capital expenditure $1.4M $1.7M $0.4M $1.0M $1.8M $0.6M $0.7M $0.4M $0.5M $1.0M
Free cash flow −$9.5M −$3.6M $29.6M $44.9M $50.0M $63.7M $31.3M $12.4M −$16.2M −$110M
Depreciation and amortization $0.9M $1.2M $1.4M $1.4M $1.4M $1.4M $1.2M $0.9M $0.9M $1.1M
Stock-based compensation $8.5M $10.5M $11.7M $13.5M $13.4M $15.4M $16.3M $14.0M $12.4M $9.5M
Balance sheet
Cash and short-term investments $141M $143M $257M $312M $368M $433M $135M $136M $102M $84.9M
Finance lease liabilities — — — — — — — — $5.0M $7.5M
Current assets $174M $170M $299M $354M $409M $478M $519M $433M $439M $347M
Current liabilities $50.3M $70.4M $53.0M $59.5M $65.9M $74.4M $91.4M $87.7M $100.0M $145M
Inventory $0.8M $0.8M $1.0M $1.1M $1.3M $1.0M $1.2M $1.4M $1.7M $1.9M
Property and equipment, net $5.0M $5.3M $4.4M $3.9M $4.1M $3.1M $2.6M $2.0M $2.1M $2.2M
Intangible assets $27.8M $26.1M $24.5M $23.0M $21.6M $20.1M $18.6M $121M $114M $117M
Total assets $210M $205M $332M $484M $533M $594M $634M $648M $656M $489M
Total liabilities $79.0M $74.0M $56.7M $72.8M $80.2M $88.9M $107M $104M $118M $162M
Preferred stock — $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Shareholders' equity $131M $131M $275M $411M $453M $505M $527M $545M $539M $327M
Margins
Operating margin −12.7% −10.2% 11.3% 10.0% 11.0% 15.7% 2.5% −7.2% −20.5% −70.0%
EBITDA margin −12.1% −9.5% 12.0% 10.7% 11.5% 16.2% 3.0% −6.8% −20.0% −69.4%
Net margin −12.3% −9.4% 13.1% 50.9% 9.4% 12.3% 2.5% 1.3% −9.5% −102.0%
FCF margin −6.5% −2.2% 15.3% 19.8% 20.1% 23.7% 12.3% 6.4% −8.2% −51.1%
Returns
Return on capital employed −11.6% −12.5% 7.8% 5.4% 5.8% 8.1% 1.2% −2.5% −7.3% −44.0%
Return on equity −13.7% −11.9% 12.4% 33.7% 5.4% 6.9% 1.2% 0.5% −3.5% −50.9%
Return on assets −8.6% −7.5% 9.4% 28.3% 4.6% 5.9% 1.0% 0.4% −2.9% −38.5%
Return on tangible equity −17.4% −14.8% 10.0% 29.8% 5.4% 6.8% 1.2% 0.6% −4.5% −104.9%
Growth
Revenue growth — 13.1% 17.0% 17.6% 9.2% 8.3% −5.3% −24.3% 3.2% 8.7%
Net income growth — — — 358.4% −79.8% 42.1% −81.1% −60.0% −853.3% —
EPS growth — — — 339.6% −80.1% 38.1% −81.0% −63.6% −925.0% —
FCF growth — — — 51.7% 11.2% 27.4% −50.8% −60.3% −230.8% —
Share count change — 3.0% 18.6% 3.4% 0.6% 3.1% 0.1% 1.0% 1.0% 1.3%
Financial health
Current ratio 3.5x 2.4x 5.6x 6.0x 6.2x 6.4x 5.7x 4.9x 4.4x 2.4x
Quick ratio 3.4x 2.4x 5.6x 5.9x 6.2x 6.4x 5.7x 4.9x 4.4x 2.4x
Capital allocation
Capex / revenue 1.0% 1.0% 0.2% 0.4% 0.7% 0.2% 0.3% 0.2% 0.2% 0.5%
Stock comp / revenue 5.9% 6.3% 6.0% 5.9% 5.4% 5.7% 6.4% 7.3% 6.3% 4.4%
Quality scores
Piotroski F-score — 3.0 5.0 4.0 4.0 5.0 3.0 3.0 2.0 2.0
Altman Z'' −0.3 −1.2 7.1 8.8 9.3 10.0 8.9 8.1 6.9 0.1
Accruals ratio −4.7% −6.5% −1.8% 17.1% −5.6% −5.5% −4.2% −1.6% −0.5% −19.4%

Source: SEC EDGAR XBRL filings (CIK 0001347178). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open